Yahoo
NYSE - Nasdaq Real Time Price USD

McKesson Corporation (MCK)

1,006.57 +6.66 (+0.67%)
As of 9:37:48 AM EST. Market Open.
Trade MCK on Coinbase
MCK Q2 2027 earnings call
Today at 4:30 PM EST
Chart Range Bar
Loading chart for MCK

What's happening with MCK?

6m ago
Powered by Yahoo Scout

McKesson is entering its fiscal second-quarter report with strong demand across pharmaceutical distribution, specialty care, oncology, and GLP-1 therapies. Analysts expect continued earnings and revenue growth, while pricing pressure, cybersecurity costs, and a negative earnings-signal model create near-term uncertainty.

Powered by Yahoo Scout
  • Previous Close 999.91
  • Open 990.89
  • Bid 1,010.72 x 8000
  • Ask --
  • Day's Range 1,006.57 - 1,015.73
  • 52 Week Range 723.68 - 1,030.27
  • Volume 25,501
  • Avg. Volume 849,537
  • Market Cap (intraday) 117.356B
  • Beta (5Y Monthly) 0.28
  • PE Ratio (TTM) 26.94
  • EPS (TTM) 37.36
  • Earnings Date Nov 4, 2026
  • Forward Dividend & Yield 3.76 (0.38%)
  • 1y Target Est 1,026.07
  • Morningstar Rating Rating available with Stock Picks access

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: North American Pharmaceutical, Oncology & Multispecialty, Prescription Technology Solutions, and Medical-Surgical Solutions. The company distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products; delivers products to retail pharmacies, hospitals, long-term care centers, clinics, and institutions; and provides logistics and distribution services for manufacturers. It also provides consulting, outsourcing, technological, and other services, as well as sells financial, operational, and clinical solutions to pharmacies; gene therapy with InspiroGene, practice consulting, and vaccine distribution services; and technology solutions, as well as research, insights, technologies, and services to improve cancer and specialty care. In addition, the company helps in solving medication access, affordability, and adherence challenges for patients by working across healthcare to connect patients, pharmacies, providers, pharmacy benefit managers, health plans, and biopharma companies. Further, it offers technology services, which includes electronic prior authorization, prescription price transparency, benefit insight, dispensing support services, patient enrollment, third-party logistics, and wholesale distribution support; medical-surgical supplies, laboratory equipment, pharmaceutical distribution, logistics, and other services to healthcare providers, including physician offices, surgery centers, hospital reference labs, nursing homes, hospice and home health care agencies, government facilities, and online marketplaces and retailers. McKesson Corporation was founded in 1833 and is headquartered in Irving, Texas.

www.mckesson.com

41,600

Full Time Employees

March 31

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Performance Overview

Trailing total returns as of 11/4/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

MCK
23.08%
S&P 500 (^GSPC)
12.13%

1-Year Return

MCK
20.06%
S&P 500 (^GSPC)
13.35%

3-Year Return

MCK
125.29%
S&P 500 (^GSPC)
76.12%

5-Year Return

MCK
362.97%
S&P 500 (^GSPC)
64.01%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q1 FY27
Revenue 105.38B
Earnings 614M
Profit Margin 0.58%

Q2

FY26

Q3

FY26

Q4

FY26

Q1

FY27

0
20B
40B
60B
80B
100B
0.6%
0.8%
1.0%
1.2%
1.4%
1.6%

Analyst Insights

View More

Analyst Price Targets

845.00 Low
1,026.07 Average
1,006.57 Current
1,207.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 10/20/2026
Analyst Mizuho
Rating Action Maintains
Rating Neutral
Price Action Raises
Price Target 905 -> 1020

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    1.12%

  • Return on Assets (ttm)

    4.74%

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    410.98B

  • Net Income Avi to Common (ttm)

    4.59B

  • Diluted EPS (ttm)

    37.36

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    5.16B

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    6.8B

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: